



BioCryst Pharmaceuticals Inc.  
2190 Parkway Lake Drive  
Birmingham, AL 35244

Durham, NC Office  
4505 Emperor Blvd, Suite 200  
Durham, NC 27707

Visit IR website [↗](#)  
Sign-up for email alerts [↗](#)

**NASDAQ: BCRX <sup>1</sup>**

|               |                            |
|---------------|----------------------------|
| Last Trade:   | 9.55                       |
| Trade Time:   | 4:06 PM ET<br>Nov 20, 2009 |
| Change:       | -0.85<br>(8.173%)          |
| Day Range     | 9.54 - 10.00               |
| 52-Week Range | 0.85 - 13.47               |
| Volume        | 6,734,100                  |

**Share Related Items <sup>2</sup>**

|                      |         |
|----------------------|---------|
| Market Cap. (Mil) \$ | 370.763 |
| Shares Out (Mil)     | 38.823  |
| Float (Mil)          | 31.681  |

\*Mil = Millions

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

<sup>2</sup> Share Related information provided by Reuters. Data as of Nov 20, 2009.

**Company Profile**

BioCryst Pharmaceuticals designs, optimizes, and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. BioCryst has progressed two novel compounds that are in late-stage pivotal trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. The Company's strategic alliances with the U.S. Department of Health and Human Services (HHS)/Biomedical Advanced Research and Development Authority (BARDA), Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited validate its scientific foundation and the utility of its product candidates. ... [\(more\)](#)

**Stock Performance**



**Press Releases** [\[ View all \]](#)

- Nov 19, 2009 [BioCryst Announces Pricing of Public Offering of Common Stock](#)
- Nov 17, 2009 [BioCryst Announces Proposed Public Offering of Common Stock](#)
- Nov 5, 2009 [BioCryst Receives First Peramivir Order From U.S. Government](#)
- Nov 4, 2009 [BioCryst's Partner Shionogi Files for Peramivir Regulatory Approval in Japan](#)
- Oct 29, 2009 [BioCryst to Present at Oppenheimer Healthcare Conference](#)

**Events** [\[ View all \]](#)

- Nov 4, 2009 [20th Annual Oppenheimer Healthcare Conference](#)
- Oct 29, 2009 11:00 AM ET [BioCryst Third Quarter 2009 Conference Call](#)

**Financials** [\[ View all \]](#)

- Mar 6, 2009 [Annual Report \(10-K\)](#)
- Apr 3, 2009 [Definitive Proxy Statement](#)
- Nov 6, 2009 [Quarterly Report \(10-Q\)](#)
- Jul 31, 2009 [Quarterly Report \(10-Q\)](#)
- May 8, 2009 [Quarterly Report \(10-Q\)](#)

